BeOne Medicines Ltd. (BeOne) disclosed that on 3 August 2026 it issued 866,073 new ordinary shares under the company’s Sixth Amended and Restated 2018 Employee Share Purchase Plan. The shares were first allotted to wholly owned subsidiary BG NC 2, Ltd. at an issue price of USD 0.0001 each and were then immediately re-transferred to BeOne to be held for future delivery to plan participants.

Key transaction data • Incremental shares: 866,073 • Percentage of pre-event issued share capital (Hong Kong line): 0.056% • Opening balance (30 June 2026): 1,426.36 million ordinary shares • Closing balance (3 August 2026): 1,427.23 million ordinary shares

The newly issued shares are not treated as outstanding under Swiss law until granted to employees; therefore, no immediate dilution arises for existing shareholders. BeOne confirmed full compliance with Hong Kong Listing Rules and other regulatory requirements.

The company’s RMB-denominated shares traded on Shanghai’s STAR Market (stock code 688235) were unchanged at 115.06 million, leaving BeOne’s total share capital at 1,542.29 million shares across both listings.